NEXThaler® is a new dry powder inhaler designed to be more effective and efficient than current dry powder inhalers available on the market. NEXThaler® is an intuitive device with an inhalation sequence that is as simple as possible (Open-Inhale-Close) resulting in accurate delivery of the drug product. NEXThaler® also incorporates an innovative full dose feedback system, activated only after full dose delivery ensuring compliance. A recent study shows that NEXThaler® is more efficient and preferred to use and own when compared to other leading DPIs on the market (Linnane et al., 2012).

Chiesi Pharmaceuticals, which started up in 1935 as a small family company is today an international company in the pharmaceutical sector and operates in all 5 continents with 25 direct branches, 3 manufacturing plants and 4 research centres situated in Parma (Italy), Paris, Rockville (Maryland - USA) and Chippenham (UK). The Company's history of continual development is founded on concepts which constitute the basis for its management: strategic innovation, internationalization and ability to plan taking care in the creation of socially compatible economic values. Chiesi aim is to be recognised as a research-focused international Group, able to develop and commercialise innovative pharmaceutical solutions to improve the quality of human life. Chiesi wants to maintain a high quality entrepreneurial team characterised by self confidence and a collaborative spirit. The main goal is to combine commitment to results with integrity, operating in a socially and environmentally responsible manner